Despite a recent decline in its share price, BioNTech finds itself at the center of bullish analyst sentiment. Several prominent investment banks have recently raised their price targets for the German biotech firm, painting a picture of substantial potential growth even as the broader market remains hesitant.
Revised Targets Highlight Bullish Outlook
Leading the charge, Berenberg Bank issued a significant update on Friday, December 12, elevating its price objective for BioNTech to $155 from a previous $150. This positions Berenberg among the most optimistic voices covering the stock.
This move was supported by other major institutions. Both BMO Capital Markets and Citigroup reaffirmed their “Buy” ratings on the company’s shares. Furthermore, just two days prior, H.C. Wainwright increased its earnings per share (EPS) forecast for the fourth quarter of 2026 to $1.14. This adjustment signals a focus among researchers on the company’s medium-term profitability rather than short-term quarterly fluctuations.
The consensus view is clear: out of 15 analysts monitoring the stock, ten recommend purchasing it. The average price target currently stands at approximately $138, suggesting a potential upside of around 45% from recent trading levels.
Should investors sell immediately? Or is it worth buying BioNTech?
Market Performance Tells a Different Story
The market has yet to align with this optimistic analysis. On Friday, BioNTech shares closed at $94.81 on the Nasdaq, marking a decline of 1.24%. Trading on the Xetra exchange in Frankfurt mirrored this trend, with the stock falling 1.52% to €81.05. This places the company’s market capitalization at about $22.8 billion.
Year-to-date, the equity has lost nearly one-third of its value. This downward pressure was partly triggered by mixed quarterly results released in November. While the company’s revenue of $1.78 billion surpassed expectations, its earnings per share fell short of analyst forecasts.
Long-Term Focus Shifts to Oncology Pipeline
Market experts are increasingly looking beyond near-term volatility to BioNTech’s core future driver: its oncology pipeline. The Mainz-based company is progressing several cancer treatments toward commercialization. H.C. Wainwright’s emphasis on 2026 earnings expectations underscores this shifting focus toward long-term revenue generation beyond its COVID-19 business.
Whether the stock can regain momentum will likely depend on clinical trial updates and tangible progress within its development portfolio. From a technical perspective, the shares are currently trading in the lower part of their 52-week range, which spans from $81 to $129. A sustained breakout above the $95 resistance level could pave the way for a move toward the $100 threshold.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from December 13 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 13.
BioNTech: Buy or sell? Read more here...
